Literature DB >> 3793280

A haemodynamic study of the effects of combined slow-calcium channel blockade (nisoldipine) and beta-blockade (metoprolol) in coronary heart disease.

B Silke, S P Verma, K A Midtbo, P Müller, M A Frais, G Reynolds, S H Taylor.   

Abstract

The interaction of a new slow-calcium blocker (nisoldipine) and the beta-blocker metoprolol was evaluated in 16 patients with stable angina. Haemodynamic parameters were determined in a control rest and exercise period. Patients were then randomised equally to nisoldipine (4-8 micrograms/kg) or metoprolol (10 mg) and the haemodynamics of monotherapy assessed; finally the second drug was administered and the effects of combination determined. At rest nisoldipine reduced systemic blood pressure and vascular resistance (P less than 0.01); heart rate, cardiac and stroke volume indices increased (P less than 0.01) at an unchanged pulmonary artery occluded pressure. Metoprolol alone reduced heart rate (P less than 0.05) and increased the pulmonary artery occluded pressure (P less than 0.05). Combination therapy reduced systemic blood pressure and vascular resistance (P less than 0.01); cardiac index and pulmonary artery occluded pressure increased (P less than 0.01) at an unchanged heart rate. The effect of combination was influenced by the order of administration; an improvement in cardiac performance was particularly evident when nisoldipine was added to metoprolol. The interaction during dynamic exercise was similar to that at rest. Thus these data indicated the haemodynamic safety of concurrent nisoldipine/metoprolol therapy; the addition of nisoldipine to metoprolol appeared to offset in part the cardiodepressant properties of beta-blockade.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3793280     DOI: 10.1016/0167-5273(86)90147-6

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil.

Authors:  L J van Woerkens; N R Baas; W J van der Giessen; P D Verdouw
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

Review 2.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

3.  Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.

Authors:  B Silke; S P Verma; S Guy
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

Review 4.  The pharmacology of nisoldipine.

Authors:  A Knorr
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

5.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Authors:  Geeta Gulati; Siri Lagethon Heck; Anne Hansen Ree; Pavel Hoffmann; Jeanette Schulz-Menger; Morten W Fagerland; Berit Gravdehaug; Florian von Knobelsdorff-Brenkenhoff; Åse Bratland; Tryggve H Storås; Tor-Arne Hagve; Helge Røsjø; Kjetil Steine; Jürgen Geisler; Torbjørn Omland
Journal:  Eur Heart J       Date:  2016-02-21       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.